早期乳腺癌的最佳辅助化疗和靶向治疗——CDK4/6抑制剂：美国临床肿瘤学会快速指南更新临床见解 - Suppr

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights.

作者信息

Caswell-Jin Jennifer L, Freedman Rachel A, Hassett Michael J, Tang Hao, Garrett-Mayer Elizabeth, Somerfield Mark R, Giordano Sharon H

机构信息

Stanford University School of Medicine, Stanford, CA.

Dana-Farber Cancer Institute, Boston, MA.

出版信息

JCO Oncol Pract. 2025 Mar;21(3):287-291. doi: 10.1200/OP-24-00663. Epub 2024 Sep 20.

DOI:10.1200/OP-24-00663

PMID:39303175

Abstract

摘要

相似文献

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights.早期乳腺癌的最佳辅助化疗和靶向治疗——CDK4/6抑制剂：美国临床肿瘤学会快速指南更新临床见解

JCO Oncol Pract. 2025 Mar;21(3):287-291. doi: 10.1200/OP-24-00663. Epub 2024 Sep 20.

Erratum: Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights.勘误：早期乳腺癌的最佳辅助化疗和靶向治疗——CDK4/6抑制剂：美国临床肿瘤学会快速指南更新临床见解。

JCO Oncol Pract. 2025 Jan 16:OP2400891. doi: 10.1200/OP-24-00891.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.早期乳腺癌最佳辅助化疗和靶向治疗的选择：ASCO 临床实践指南重点更新。

J Clin Oncol. 2018 Aug 10;36(23):2433-2443. doi: 10.1200/JCO.2018.78.8604. Epub 2018 May 22.

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.早期乳腺癌的最佳辅助化疗和靶向治疗——细胞周期蛋白依赖性激酶 4 和 6 抑制剂：ASCO 指南快速推荐更新。

J Clin Oncol. 2024 Jun 20;42(18):2233-2235. doi: 10.1200/JCO.24.00886. Epub 2024 May 20.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.早期乳腺癌最佳辅助化疗和靶向治疗的选择：ASCO 指南更新。

J Clin Oncol. 2021 Feb 20;39(6):685-693. doi: 10.1200/JCO.20.02510. Epub 2020 Oct 20.

Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.阿贝西利联合内分泌治疗用于高危早期乳腺癌的治疗：美国临床肿瘤学会最佳辅助化疗和靶向治疗指南快速推荐更新

J Clin Oncol. 2022 Jan 20;40(3):307-309. doi: 10.1200/JCO.21.02677. Epub 2021 Dec 8.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update Summary.早期乳腺癌最佳辅助化疗和靶向治疗的选择：美国临床肿瘤学会临床实践指南重点更新摘要

J Oncol Pract. 2018 Aug;14(8):508-510. doi: 10.1200/JOP.18.00207. Epub 2018 Jun 20.

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.内分泌治疗后或激素受体阴性转移性乳腺癌的化疗与靶向治疗：美国临床肿瘤学会指南快速推荐更新

J Clin Oncol. 2023 Feb 20;41(6):1318-1320. doi: 10.1200/JCO.22.02807. Epub 2023 Jan 10.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.激素受体阳性乳腺癌妇女的辅助内分泌治疗：ASCO 临床实践指南更新焦点。

J Clin Oncol. 2019 Feb 10;37(5):423-438. doi: 10.1200/JCO.18.01160. Epub 2018 Nov 19.

Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.人表皮生长因子受体2阴性转移性乳腺癌的化疗和靶向治疗：内分泌预处理或激素受体阴性患者的美国临床肿瘤学会指南快速推荐更新

J Clin Oncol. 2022 Sep 10;40(26):3088-3090. doi: 10.1200/JCO.22.01533. Epub 2022 Aug 4.

引用本文的文献

Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers.优化早期乳腺癌的辅助治疗：来自加拿大各中心的多学科策略与创新模式

Curr Oncol. 2025 Jul 14;32(7):402. doi: 10.3390/curroncol32070402.

Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis.HR+/HER2-早期乳腺癌的真实世界NATALEE和monarchE合格人群特征：美国电子健康记录数据库分析

ESMO Open. 2025 Jun;10(6):105304. doi: 10.1016/j.esmoop.2025.105304. Epub 2025 Jun 13.

Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?早期激素受体阳性、人表皮生长因子受体2阴性乳腺癌的辅助靶向治疗：奥拉帕利、阿贝西利还是瑞博西尼——哪一种、如何使用以及适用于谁？

Geburtshilfe Frauenheilkd. 2025 Apr 22;85(6):590-598. doi: 10.1055/a-2562-8469. eCollection 2025 Jun.

Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer.临床医生指南：早期乳腺癌患者使用CDK4/6抑制剂的专家见解

Ther Adv Med Oncol. 2025 Mar 20;17:17588359251326710. doi: 10.1177/17588359251326710. eCollection 2025.

Exploring the Potential of Adjuvant CDK4/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All.探索辅助性CDK4/6抑制剂在激素受体阳性早期乳腺癌中的潜力：适用于所有人的一致方法。

Cancers (Basel). 2025 Feb 7;17(4):561. doi: 10.3390/cancers17040561.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献